Skip to main content
. Author manuscript; available in PMC: 2016 Jan 2.
Published in final edited form as: Biochem Biophys Res Commun. 2014 Nov 13;456(1):7–12. doi: 10.1016/j.bbrc.2014.11.010

Figure 2. Mdivi-1 enhances TRAIL sensitivity in patient-derived primary epithelial ovarian cancer cells.

Figure 2

(A) Characteristics of the ovarian cancer patients. (B) Primary epithelial ovarian cancer cells isolated from the three patients were treated with TRAIL alone, mdivi-1 alone, or with the combination at indicated concentrations for 16 h. Cell survival was measured by CellTiter-Blue. Data represent the mean ± S.D. * P<0.05, ** P<00.1, *** P<0.001.